Experimental Approach
We screened out the small-molecule compound NVP-BHG712 targeting CTSK by molecular docking, and studied its pharmacological effect on bone resorption function of osteoclasts. To this end, we evaluated bone mass changes in postmenopausal mice by μCT, ELISA, and H&E staining. In addition, we also investigated the effects of NVP-BHG712 on osteoclast differentiation, bone resorption function and expression of osteoclast differentiation related factors in vitro.